Together with others, we have demonstrated that the combination of AKT and EGFR inhibitors could be of benefit in patients with EGFR mutations [21] [22], however, even when blocking AKT, tumor regrowth could occur through the activation of other downstream regulators, via Src/FAK [22, 23]. The gene discussed is AKT1; the disease is neoplasm.